The fixed-effects model analysis showed that, the overall HR was 1.05 (95% CI: 0.80–1.36, p = 0.74), indicating that different HER2 GCN level had no prognostic value on the trastuzumab-based treatment outcomes in HER2-positive breast cancer patients. Here, ERBB2 is linked to breast carcinoma.